medline.ch Gastroenterologie Magen-Darm Entzündliche Darmerkrankungen

	Longitudinal Endoscopic Analysis of Ulcerative Colitis-Associated Neoplasia. Gastro Hep Adv Wakisaka Y, Sugimoto S, Iwao Y, Kawaida M, Shimoda M, Keio IBD Collaborators, Kanai T. PMID: 42732317 [PubMed]
	6PPDQ exposure enhances susceptibility to ulcerative colitis by disturbing MMP9, PTGS2, and PPARG homeostasis: an integrative network toxicology and in vivo study. Chem Biol Interact Li X, Xu X, Cai Y, Luo X, Zhong H, Yin H, Zeng Y, Chen Z. PMID: 42731663 [PubMed - as supplied by publisher]
	A therapeutic atlas of monogenic inflammatory bowel disease. J Crohns Colitis Yeh PJ, Charlesworth JEG, Taylor H, Ashton JJ, Nash K, Lam KH, de Ridder L, Vuijk SA, Ye Z, Huang Y, Bildstein T, Haller W, Jones KDJ, Shouval DS, Weiss B, Lau YL, Bui-Thi-Thuy Q, Muise AM, Richards D, Travis S, Turner D, Uhlig HH. PMID: 42731022 [PubMed - indexed for MEDLINE]
	Comparative effectiveness and safety of risankizumab vs ustekinumab in patients with Crohn's disease: a propensity score-matched multicenter retrospective cohort study. Crohns Colitis 360 Sawaf B, Battistin U, Abu-Rumaileh M, Gerges KM, Hallak Y, Abbarh S, Batikh E, Hadaki N, Elhadi M, Regueiro M, Al-Haddad M. PMID: 42730438 [PubMed]
	Anti-TNF therapy attenuates the diagnostic utility of leucine-rich Î±2-Glycoprotein 1 for endoscopic activity in ulcerative colitis. Ther Adv Gastroenterol Dejima A, Takatori H, Miyazawa M, Okafuji H, Hayashi T, Seki A, Nio K, Iida N, Yamada S, Shimakami T, Toyama T, Yamashita T. PMID: 42729529 [PubMed]
	Acceptability and tolerability of risankizumab maintenance therapy administered via on-body injector in patients with Crohn's disease: Results of the ACCEPT-OBI study. Ther Adv Gastroenterol Buisson A, Gebara K, Caron B, Boschetti G, Gilletta de Saint Joseph C, Nachury M, Brixi H, Juillerat P, Serrero M, Vuitton L, Hebuterne X, Caillo L, Blain A, Laharie D, Peyrin-Biroulet L, Altwegg R, Le Cosquer G, Pereira B, Fumery M. PMID: 42729518 [PubMed]
	Bridging preclinical and clinical efficacy of SIK2/SIK3 inhibition in inflammatory bowel disease through integrated murine, patient-derived models, and phase 2a trial-based analyses. J Crohns Colitis Giorio L, De Vos S, Colli ML, Merciris D, Vissers E, Innocenti T, Kolb F, Ferrante M, Sabino JG, Vermeire S, Arnauts K, Verstockt B. PMID: 42728025 [PubMed - indexed for MEDLINE]
	Isolated perianal fistulizing Crohn's disease in contemporary clinical practice: a multicenter ECCO-CONFER cohort study. J Crohns Colitis Basnayake K, Subhaharan D, Drobne D, Deepak P, Samaan S, Mantia A, Nardone OM, Howard JR, Romero-Salazar FL, Ramírez Alcázar P, Centritto A, Verstockt B, Reenaers C, Hanna L, Saibeni S, Filip R, Hale M, Pugliese D, Savarino EV, Ribaldone DG, Geldof J, Gawron-Kiszka M, Bezzio C, Gojdi, Zagórowicz E, Jauregui-Amezaga A, Basnayake T, Festa S, Alexander JL, Cooney R, Raine T. PMID: 42728024 [PubMed - indexed for MEDLINE]
	Biopsychosocial model of inflammatory bowel diseases: The impact of multisystem comorbidity and mental health on patients' quality of life. Pol Merkur Lekarski Romash I, Romash I, Yatsynovych V, Dzvonkovska T, Reinert U. PMID: 42726830 [PubMed - indexed for MEDLINE]
	Mesalazine-Induced Myocarditis Following Dose Escalation in Ulcerative Colitis: A Diagnostic Challenge. Eur J Case Rep Intern Med Vidal López A, Esteve Pastor MA, Romero Martínez M, Carrillo Mora LM, Salinas García J, Agulló López C, Pascual Figal DA. PMID: 42725157 [PubMed]
	Efficacy and tolerability of janus kinase inhibition strategies for moderate-to-severe Crohn's disease: A systematic review and bayesian network meta-analysis. Ther Adv Gastroenterol Wazir HU, Mehta K, Shabbir MS, Islam MR, Maaz M, Muzaffar M, Ehsan N, Aliha S, Chauhan A, Khurram A, Saffouri G. PMID: 42724432 [PubMed]
	High prevalence of fatigue in patients with inflammatory bowel disease: association with physical activity intensity and sedentary behavior. Front Public Health Herrera MD, Aguiló A, Tauler P, Mingorance JA, Ginard D, Puchol E, Martínez S. PMID: 42724157 [PubMed - indexed for MEDLINE]
	From triggers to interfaces: polymer-stabilized nano-co-crystals for robust mesalazine delivery in UC. Daru Khan A, Kumar S, Singh AR, Agarwal M, Kailasiya A, Qureshi J. PMID: 42722949 [PubMed - indexed for MEDLINE]
	Long-term outcomes of top-down therapy versus a conventional step-up strategy in adults newly diagnosed with Crohn's disease: 5-year follow-up of the PROFILE trial. Lancet Gastroenterol Hepatol Noor NM, Sharip MT, Zheng H, Widmer B, Brezina B, Patel KV, Dowling F, Bhatti S, Alsmade N, Ahmad T, Banim PJ, Berrill JW, Cooney R, De La Revilla Negro J, de Silva S, Din S, Durai D, Gordon JN, Hart AL, Irving PM, Johnson M, Kent AJ, Kok KB, Moran GW, Mowat C, Patel P, Raine T, Saich R, Sharpstone D, Smith MA, Steel A, Subramanian S, Wiles A, Williams HRT, Lindsay JO, Kennedy NA, McKinney EF, Lyons PA, Smith KGC, Lee JC, Robertson DS, Parkes M, PROFILE Study Group. PMID: 42721994 [PubMed - as supplied by publisher]
	Real-World Effectiveness and Safety of Upadacitinib in Patients With Crohn's Disease-A Multicentre Prospective Study From the Italian Group for the Study of Inflammatory Bowel Diseases (IG-IBD). Aliment Pharmacol Ther Barberio B, D'Amico F, Laterza L, Bezzio C, Dragoni G, Viola A, Todeschini A, Principi M, Onali S, Viganò C, Cappello M, Mocci G, Viscido A, Bodini G, Ribaldone DG, Marafini I, Pugliese D, Massari A, Saibeni S, Pastorelli L, Melotti L, Bergna IMB, Gravina AG, Desideri F, Merli M, Bertani L, Spagnuolo R, Imperatore N, Ferracane C, Quadarella A, Luna ID, Tortorella V, Mazzuoli S, Felice C, Balestrieri P, Balducci D, Aratari A, Buda A, Danese S, Scaldaferri F, Armuzzi A, Zingone F, Chahuan J, Savarino EV. PMID: 42720163 [PubMed - as supplied by publisher]
	Outcomes and Complications of Shoulder Arthroplasty in Patients With Inflammatory Bowel Disease: A Large Insurance Claims Matched Cohort Analysis. J Am Acad Orthop Surg Glob Res Rev Khazi-Syed D, Chang J, Bohn C, Hand C, Gornbein C, Singh H, Mirle V, Gamsarian V, Harkin W, Eilen H, Varano M, Forsythe B. PMID: 42715397 [PubMed - indexed for MEDLINE]
	Gut microbiota-derived metabolites and IL-22 signaling in inflammatory bowel disease: context-dependent regulation of mucosal repair and inflammation. Front Immunol Shi P, He X, Zhao L, Pan W, Zhou M, Zhang T. PMID: 42713082 [PubMed - indexed for MEDLINE]
	Probiotic-Derived Extracellular Vesicles as Potential Nano-Immunotherapeutic Platforms in IBD: A Clinician's Perspective. Int J Nanomedicine Jeon HJ, Choe AR, Kim SE. PMID: 42712961 [PubMed - indexed for MEDLINE]
	Association of nutritional indices with early clinical remission in patients with moderate-to-severe ulcerative colitis treated with vedolizumab. Ther Adv Gastroenterol Zhang H, Wang Y, Wu J, Wang H, Min C, Meng P, Liu H, Mao T, Xu Y, Jin L, Wang B, Han X, Liu A, Ding X. PMID: 42712941 [PubMed]
	Long-term real-world effectiveness and safety of mirikizumab in ulcerative colitis: 52-Week results from an expanded international two-center retrospective cohort study. Ther Adv Gastroenterol Levartovsky A, Luká, Abitbol CM, Vlková K, Ben-Horin S, Luká, Kopylov U. PMID: 42712747 [PubMed]

Artikel 1 - 20 / 58805

Seite 1 von 2941



		Zeitfenster

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Datenschutzerklärung / Privacy Policy \| Werbung